Barr Pharmaceuticals
An American pharmaceutical manufacturer focused primarily on generic medicines, specialty products, and women's health.
Last updated August 31, 2026
AI crawler reads
No AI crawler has read this profile since Oct 28, 2026.
Overview
Barr Pharmaceuticals was an American pharmaceutical company that developed, manufactured, and marketed generic and specialty medicines. The business began as Barr Laboratories in New York in 1970, founded by Edwin A. Cohen, and later grew into a multinational drug manufacturer with operations in approximately 30 countries. Its commercial identity was built largely around the generic-drug market, which accounted for roughly three-quarters of revenue according to descriptions of the company before its acquisition. Women's health became an especially important area: oral contraceptive products represented a significant share of sales, and the company expanded its position through products such as Plan B emergency contraception and hormone-related medicines. The company's growth combined regulatory expertise, litigation, product development, and acquisitions. During the 1990s, Barr secured approvals for several important generic medicines, including generic zidovudine, or AZT, and became the first company approved by the U.S. Food and Drug Administration to market generic warfarin, a medicine previously associated with DuPont. It also prevailed after a prolonged legal dispute with Eli Lilly over the right to market a generic version of Prozac. These events reinforced Barr's reputation as an aggressive participant in patent challenges and abbreviated-drug-approval pathways. Barr's development was not without serious regulatory controversy. Beginning in 1991, the company became involved in a dispute concerning its handling of out-of-specification laboratory test results and alleged violations of current good manufacturing practice requirements. A 1993 court decision arising from the matter contributed to broader industry interpretations of how pharmaceutical companies should investigate and handle out-of-specification results. The episode became a prominent part of Barr's regulatory history and illustrated the compliance risks associated with generic-drug manufacturing. The company broadened its capabilities through a series of acquisitions. It bought Duramed Pharmaceuticals in 2001 in a stock transaction valued at approximately $589 million, acquired Endeavor Pharmaceuticals in 2003, and purchased Women's Capital in 2004. It then acquired the Croatian pharmaceutical company Pliva in 2006, substantially expanding its international manufacturing and commercial presence. These transactions supported Barr's combination of generic pharmaceuticals, specialty medicines, and women's-health products. Bruce L. Downey became president in 1993 and chairman and chief executive officer in 1994. Under his leadership, Barr expanded from a U.S.-centered generic-drug producer into a broader international pharmaceutical group. On December 23, 2008, Teva Pharmaceutical Industries completed its acquisition of Barr. Contemporary reporting and reference material commonly placed the transaction's estimated value at approximately $7.46 billion, although the consideration structure and valuation varied with market conditions. Barr subsequently ceased operating as an independent public pharmaceutical company and its assets and activities were integrated into Teva's businesses, including Teva Active Pharmaceutical Ingredients. The Barr brand is therefore principally significant as the predecessor of a major Teva expansion rather than as an active standalone pharmaceutical company.
History
Barr Pharmaceuticals originated as Barr Laboratories, founded in New York in 1970 by Edwin A. Cohen. The company entered the pharmaceutical market with an emphasis on developing and manufacturing medicines that could compete with established branded products after patent or exclusivity protections ended. Over time, its capabilities expanded from a domestic generic-drug operation into a multinational business covering generic medicines, specialty pharmaceuticals, and women's health. The company's regulatory and legal history became particularly important during the 1990s. Starting in 1991, Barr was involved in a controversy over alleged current good manufacturing practice violations involving the handling of out-of-specification test results. The matter resulted in litigation, and Barr lost a related lawsuit in 1993. The decision influenced subsequent interpretations within the pharmaceutical industry and regulatory community concerning the investigation and disposition of atypical or failed laboratory results. In the same year, Barr settled a patent infringement dispute and began distributing generic tamoxifen citrate. Bruce L. Downey joined as president in 1993 and became chairman and chief executive officer in 1994. Barr achieved a series of notable generic-drug milestones in the middle and late 1990s. In 1995, it received authorization to manufacture and sell generic zidovudine, or AZT, an HIV/AIDS treatment. In 1996, it became the first company to receive FDA approval to market generic warfarin, a widely used anticoagulant that had previously been sold only by DuPont. Barr also developed a reputation for challenging pharmaceutical patents. After a five-year court battle with Eli Lilly, it began selling generic fluoxetine, the active ingredient in Prozac, in August 2001. Acquisitions became central to Barr's next phase. In 2001, the company acquired Duramed Pharmaceuticals in a stock transaction reported at approximately $589 million. Duramed added scale and expertise in women's health and specialty products. Barr acquired Endeavor Pharmaceuticals in 2003 and Women's Capital in 2004. The Women's Capital transaction brought Plan B emergency contraception into Barr's portfolio and reinforced the company's position in reproductive health. In October 2006, Barr acquired Pliva, a Croatian pharmaceutical company. The Pliva transaction broadened Barr's geographic reach, manufacturing base, and portfolio of generic medicines. By the period immediately preceding its sale, Barr operated in approximately 30 countries. Generic drugs generated about 75 percent of revenue, while oral contraceptives represented approximately 18 percent of sales in the descriptions used for the company. This mix made Barr different from a purely commodity-oriented generic manufacturer: its business combined high-volume generic products with specialty medicines and a concentrated women's-health franchise. Teva Pharmaceutical Industries acquired Barr on December 23, 2008. Reference accounts commonly describe the estimated transaction value as approximately $7.46 billion, though transaction valuations can differ depending on the basis used. The acquisition transformed Teva's international generic-drug scale and absorbed Barr's products, facilities, and commercial operations. Barr subsequently ceased to exist as an independent company and became part of Teva's corporate and operating structure, including Teva Active Pharmaceutical Ingredients. Its historical importance lies in demonstrating how a generic-drug manufacturer could build substantial value through patent challenges, regulatory approvals, targeted acquisitions, and specialization in women's health.
- 2008
Acquisition by Teva
[1]Teva acquired Barr on December 23, bringing the company into Teva's global pharmaceutical organization.
- 2006
Pliva acquisition
[1]Barr acquired Pliva, broadening its international operations and generic-drug manufacturing footprint.
- 2004
Women's Capital acquisition
[1]Barr acquired Women's Capital, bringing Plan B emergency contraception into its portfolio.
- 2003
Endeavor Pharmaceuticals acquisition
[1]Barr acquired Endeavor Pharmaceuticals to expand its specialty-pharmaceutical activities.
- 2001
Duramed acquisition and generic Prozac launch
[1]Barr acquired Duramed Pharmaceuticals and, after prolonged litigation with Eli Lilly, began selling generic fluoxetine.
- 1996
First FDA approval for generic warfarin
[1]Barr became the first company approved by the FDA to market generic warfarin.
- 1995
Generic AZT approval
[1]Barr received approval to manufacture and sell generic zidovudine, or AZT.
- 1993
Leadership and tamoxifen milestone
[1]Bruce L. Downey became president, Barr settled a patent case, and the company began distributing generic tamoxifen citrate.
- 1991
Good manufacturing practice controversy begins
[1]Barr became involved in a regulatory controversy concerning its handling of out-of-specification test results and alleged GMP violations.
- 1970
Barr Laboratories is founded
[1]Edwin A. Cohen founded Barr Laboratories in New York, establishing the business that later became Barr Pharmaceuticals.
Products and positioning
A generic-drug and specialty-pharmaceutical company competing through regulatory expertise, patent litigation, manufacturing scale, acquisitions, and a strong women's-health portfolio.
Oncology medicine · 1993
Generic tamoxifen citrate
Barr began distributing a generic version of tamoxifen citrate in 1993 after settling a patent infringement dispute. Tamoxifen is used in the treatment and prevention of certain forms of hormone-responsive breast cancer. The product illustrated Barr's strategy of entering clinically important markets through patent resolution and generic commercialization.
Antiviral medicine · 1995
Generic zidovudine (AZT)
Barr received approval in 1995 to manufacture and sell generic zidovudine, commonly known as AZT. The medicine was an important treatment for HIV infection and AIDS, making the approval a notable example of Barr's participation in expanding access to established therapies through generic production.
Anticoagulant · 1996
Generic warfarin
Barr became the first company to receive FDA approval to market generic warfarin in 1996. Warfarin is an anticoagulant used to reduce the risk of blood clots. The approval was commercially and regulatorily significant because the product had previously been sold only by DuPont.
Antidepressant · 2001
Generic fluoxetine
After a five-year legal dispute with Eli Lilly, Barr began selling generic fluoxetine, the active ingredient in Prozac, in August 2001. The launch demonstrated Barr's willingness to pursue patent litigation and regulatory approval for high-profile products with substantial commercial demand.
Emergency contraception
Plan B
Plan B emergency contraception entered Barr's portfolio through its 2004 acquisition of Women's Capital. The product became one of the company's most recognizable women's-health offerings and strengthened Barr's position in reproductive-health medicines.
Women's health
Oral contraceptives
Oral contraceptives were a major commercial category for Barr. Reference material describes them as contributing approximately 18 percent of company sales before the Teva acquisition. The category reflected Barr's strategic focus on women's health alongside its broader generic-drug portfolio.
Controversies
1991
Good manufacturing practice and out-of-specification testing controversy
Barr became involved in a controversy concerning alleged violations of current good manufacturing practice rules and the handling of out-of-specification laboratory results. The dispute led to litigation, and a 1993 loss for Barr contributed to later industry interpretations of FDA expectations for investigating and documenting such results.
Brand decisions
2008
Sell the company to TevaM&ABackground
Barr had become an international generic and specialty-pharmaceutical group with a substantial women's-health business.
Action taken
Teva Pharmaceutical Industries acquired Barr on December 23, 2008.
Aftermath
Barr ceased operating as an independent company and its assets and operations were integrated into Teva's global organization.
Estimated acquisition value. (2008)
2006
Acquire PlivaM&ABackground
Barr pursued international scale and a broader manufacturing and generic-medicine platform.
Action taken
Barr acquired Pliva in October 2006.
Aftermath
The acquisition expanded Barr's international operations and manufacturing footprint.
2004
Acquire Women's CapitalM&ABackground
Barr was building a stronger presence in reproductive and women's-health products.
Action taken
Barr acquired Women's Capital, the company associated with Plan B emergency contraception.
Aftermath
Plan B became part of Barr's women's-health portfolio and increased the visibility of this business area.
2003
Acquire Endeavor PharmaceuticalsM&ABackground
Barr continued expanding its specialty-pharmaceutical and women's-health portfolio.
Action taken
Barr acquired Endeavor Pharmaceuticals.
Aftermath
The deal added to Barr's specialty capabilities, although detailed post-acquisition operating effects are not specified in the reference material.
Reported transaction value. (2003)
2001
Acquire Duramed PharmaceuticalsM&ABackground
Barr sought to broaden its specialty and women's-health capabilities beyond its traditional generic-drug base.
Action taken
The company acquired Duramed Pharmaceuticals in a stock transaction described in reference material as approximately $589 million.
Aftermath
The acquisition strengthened Barr's position in women's health and contributed to its broader specialty-pharmaceutical platform.
Reported transaction value. (2001)
Sources1 sources
Cite this profile: Cite the canonical profile. /brand-wiki/barr-pharmaceuticals · Editorial policy · How profiles are compiled